Solaris Asset Management’s GSK GSK Stock Holding History

Solaris Asset Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-132	Closed	-$7K	–	278
2017 Q2	$7K	Buy	+132	New	+$7.04K	﹤0.01%	261

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Solaris Asset Management's GSK Position: Q3 2017 in Review

Solaris Asset Management sold out of GSK (GSK) in Q3 2017, closing a stake of 132 shares — an estimated $7K sold.

Solaris Asset Management first reported a position in GSK in Q2 2017 and held it in 1 quarter. The position peaked at $7K in Q2 2017. 741 funds tracked by Wall St. Rank hold GSK as of Q3 2017.

Solaris Asset Management reported no remaining GSK position as of Q3 2017 after selling out during the quarter.
Solaris Asset Management sold 132 GSK shares in Q3 2017, an estimated $7K.
Solaris Asset Management first reported a position in GSK in Q2 2017 and held it in 1 quarter.
Solaris Asset Management's GSK position peaked at $7K in Q2 2017.
741 funds tracked by Wall St. Rank held GSK as of Q3 2017.

Based on Solaris Asset Management's 13F filing for Q3 2017, filed 10 Oct 2017.